E. Ubiña Aznar
About
In The Last Decade
E. Ubiña Aznar
12 papers receiving 263 citations
Peers
Comparison fields: 5 of 44
- Epidemiology 217
- Infectious Diseases 167
- Surgery 107
- Virology 38
- Immunology 21
Countries citing papers authored by E. Ubiña Aznar
This map shows the geographic impact of E. Ubiña Aznar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Ubiña Aznar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Ubiña Aznar more than expected).
Fields of papers citing papers by E. Ubiña Aznar
This network shows the impact of papers produced by E. Ubiña Aznar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Ubiña Aznar. The network helps show where E. Ubiña Aznar may publish in the future.
Co-authorship network of co-authors of E. Ubiña Aznar
This figure shows the co-authorship network connecting the top 25 collaborators of E. Ubiña Aznar. A scholar is included among the top collaborators of E. Ubiña Aznar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Ubiña Aznar. E. Ubiña Aznar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 6 | |
| 2 | 1 | |
| 3 | 8 | |
| 4 | 2 | |
| 5 | 2 | |
| 6 | 2 | |
| 7 | [Systemic arterial hypertension in primary chronic glomerulonephritis: prevalence and its influence on the renal prognosis]. | 3 |
| 8 | 103 | |
| 9 | 5 | |
| 10 | 142 | |
| 11 | Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. Spanish Ribavirin Trial Group. | 3 |
| 12 | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.